Analysts See Big Upside in Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is among the cheap healthcare stocks to bargain heading into 2026. As of December 7, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is simply a statement Buy with each 7 analysts covering it assigning it a Buy oregon equivalent rating. With a median terms of $35, the banal has an upside imaginable of 48.75% from its existent price.

Earlier connected November 26, Chief Commercial Officer of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), Jeffrey Del Carmen, offloaded 10,983 shares of communal stock, valued astatine astir $256,244. According to the latest Form 4 filing with the Securities and Exchange Commission, Del Carmen present owns 3,962 shares of the company’s stock.

RAJ CREATIONZS / shutterstock.com

During the company’s presumption astatine the Jefferies London Healthcare Conference 2025 connected November 17, absorption highlighted plans to beforehand acquisition successful the oncology abstraction for LEMS. Driving further interest, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) disclosed its efforts to accelerate integrated maturation by targeting patients astatine assorted stages of the diagnostic journey. Despite contention successful the epilepsy market, the institution remains committed to diligent enactment and strategical acquisitions.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is simply a Florida-based commercial-stage biopharmaceutical institution focused connected treatments for radical surviving with life-threatening diseases. Founded successful 2002, the institution offers Firdapse, Fycompa, Ruzurgi, and AGAMREE.

While we admit the imaginable of CPRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.